News | July 22, 2023
Lonza delivers 5.6% CER sales growth and 30% CORE EBITDA margin
Good momentum in commercial CDMO business
Good momentum in commercial CDMO business
CMOs showed an increasing reluctance to take on debt in 2022
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Construction will begin this year with the new capacity anticipated by 2025
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Subscribe To Our Newsletter & Stay Updated
